Clinical Trials Logo

Filter by:
NCT ID: NCT02453386 Terminated - Clinical trials for Idiopathic Parkinson's Disease

Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients

TOZ-PD
Start date: July 2015
Phase: Phase 3
Study type: Interventional

Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 3-arm safety and efficacy study (Part A) with an open-label phase (Part B).

NCT ID: NCT02450331 Terminated - Clinical trials for Carcinoma, Transitional Cell

A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection

IMvigor010
Start date: October 5, 2015
Phase: Phase 3
Study type: Interventional

This Phase III, open-label, randomized, multicenter study is to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with observation in participants with muscle-invasive UC who are at high risk for recurrence following resection. Eligible participants were randomized by a 1:1 ratio into atezolizumab group or control group.

NCT ID: NCT02448589 Terminated - Clinical trials for Advanced Solid Tumors

An Investigation of TAS-119 Monotherapy

Start date: September 2014
Phase: Phase 1
Study type: Interventional

A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of TAS-119 in Patients with Advanced Solid Tumors.

NCT ID: NCT02448095 Terminated - Clinical trials for Chronic Myeloid Leukemia

Retrospective Evaluation of CML Patients in the National Compassionate Program

Start date: December 22, 2015
Phase:
Study type: Observational

This observational study aims at assessing the tolerability and safety profiles of Ponatinib, a drug used for Chronic Myeloid Leukemia patients who are Philadelphia positive. This drug is used during the chronic phase of the disease, according to the Italian national compassionate law 648/96.

NCT ID: NCT02441309 Terminated - Osteosarcoma Clinical Trials

A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)

MEMOS
Start date: October 2014
Phase: Phase 2
Study type: Interventional

This is a Bayesian designed multi-arm, multi-centre, open label phase II study. The target sample size of 40 patients will be recruited from up to 8 EU countries, but this may be revised in light of the interim analysis. Patients with relapsed or metastatic osteosarcoma will be divided into three treatment groups. They will all either have surgery or a biopsy before and after six weeks exposure to either Mifamurtide alone, Ifosfamide alone, or Mifamurtide combined with Ifosfamide. They will then receive further treatment to a maximum of 42 or 36 weeks in total (depending on Arm), with all patients being able to receive 36 weeks of Mifamurtide treatment.

NCT ID: NCT02438007 Terminated - Prostate Cancer Clinical Trials

A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC

ARMOR3-SV
Start date: June 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare galeterone to enzalutamide in men expressing androgen receptor spice variant-7 mRNA (AR-V7) in metastatic (M1) castrate resistant prostate cancer (CRPC).

NCT ID: NCT02431663 Terminated - Status Epilepticus Clinical Trials

Ketamine in Refractory Convulsive Status Epilepticus

KETASER01
Start date: April 2015
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy of intravenous administration of ketamine in the treatment of refractory convulsive status epilepticus in children compared to administration of midazolam at high doses, thiopental and / or propofol.

NCT ID: NCT02428231 Terminated - Multiple Sclerosis Clinical Trials

Tecfidera Slow-titration Study

TITRATION
Start date: April 2015
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to assess whether a 6-week titration (compared with a 1-week titration) is effective in reducing the incidence of dimethyl fumarate (DMF)-related gastrointestinal (GI) Adverse Events (AEs) in subjects with Multiple Sclerosis (MS). The secondary objective of this study is to assess whether a 6-week titration (compared with a 1-week titration) is effective in reducing the average severity and duration of GI symptoms over 12 weeks of dimethyl fumarate treatment in this study population.

NCT ID: NCT02425488 Terminated - Heart Failure Clinical Trials

Nursing Therapeutics Education and Heart Failure (HF): a Study Protocol

NEHF
Start date: April 2015
Phase: N/A
Study type: Interventional

Purpose: Heart Failure (HF) is a clinical multifactorial syndrome, it can cause arrhythmias for which international guidelines suggest the implantation of an implantable cardiac defibrillator (ICD). The educational nursing program would improve clinical outcomes in patients with HF and ICD like control their sickness, known and acknowledge symptoms, improve their skills to self-care. The main aim of this study is to assess how much the nursing-therapeutics skills and an educational intervention, in patients with HF during the follow-up period after the implantation of ICD reduces clinical costs, re-hospitalizations, and mortality at 180 days. Methods: The investigators start a multicenter randomized clinical trial. The sample is made of 128 subjects (64 patients treatment group and 64 control group). The investigators measured the self-care level administering to HF patients the "Self-Care of Heart Failure Index (SCHFI) v. 6.2", and the self-perception of own life quality using a Numeric Rating Scale from 0 to 100. Secondary outcomes recorded are i) the numbers of accesses to the ED (Emergency Department) and/or hospitalizations during the follow-up period, ii) mortality rate due to HF, and iii) infection rate of the device pocket. Data Analysis: Categorical variables will be presented in terms of frequencies and percentages. The statistical power was fixed at the 80%. Data will be considered significant for a p-value ≤ 0.05. The Cox proportional hazards model will be used to analyze mortality in subjects involved in the educational program.

NCT ID: NCT02415595 Terminated - Clinical trials for Infection, Human Immunodeficiency Virus

Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults

Start date: May 12, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find at least one dose of BMS-955176 that will be safe, effective and tolerable for HIV-1 infected treatment naive adults.